Page 121 - Read Online

Chia et al. Hepatoma Res 2019;5:9 I http://dx.doi.org/10.20517/2394-5079.2018.112 Page 13 of 14

105. Wang Y, Dong Q, Zhang Q, Li Z, Wang E, et al. Overexpression of yes-associated protein contributes to progression and poor
prognosis of non-small-cell lung cancer. Cancer Sci 2010;101:1279-85.
106. Hayashi H, Higashi T, Yokoyama N, Kaida T, Sakamoto K, et al. An imbalance in TAZ and YAP expression in hepatocellular
carcinoma confers cancer stem cell-like behaviors contributing to disease progression. Cancer Res 2015;75:4985-97.
107. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, et al. The Hippo pathway target, YAP, promotes metastasis through its TEAD-
interaction domain. Proc Natl Acad Sci U S A 2012;109:E2441-50.
108. Zhou Z, Hu T, Xu Z, Lin Z, Zhang Z, et al. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic
YAP-like peptides. FASEB J 2015;29:724-32.
109. Gibault F, Coevoet M, Sturbaut M, Farce A, Renault N, et al. Toward the discovery of a novel class of YAP-TEAD interaction
inhibitors by virtual screening approach targeting YAP-TEAD protein-protein interface. Cancers (Basel) 2018;10:E140.
110. Guerra E, Trerotola M, Aloisi AL, Tripaldi R, Vacca G, et al. The Trop-2 signalling network in cancer growth. Oncogene
2013;32:1594-600.
111. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, et al. High expression of TROP2 correlates with poor prognosis in
pancreatic cancer. Br J Cancer 2008;99:1290-5.
112. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral
cavity. Mod Pathol 2008;21:186-91.
113. Mühlmann G, Spizzo G, Gostner J, Zitt M, Maier H, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin
Pathol 2009;62:152-8.
114. Ning S, Guo S, Xie J, Xu Y, Lu X, et al. TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma. J
Gastrointest Surg 2013;17:360-8.
115. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, et al. Clinical significance of TROP2 expression in colorectal cancer. Clin
Cancer Res 2006;12:3057-63.
116. Liu T, Liu Y, Bao X, Tian J, Liu Y, et al. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and
promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS One 2013;8:e75864.
117. Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, et al. Trop-2 overexpression as an independent marker for poor overall
survival in ovarian carcinoma patients. Eur J Cancer 2010;46:944-53.
118. Chen MB, Wu HF, Zhan Y, Fu XL, Wang AK, et al. Prognostic value of TROP2 expression in patients with gallbladder cancer.
Tumour Biol 2014;35:11565-9.
119. Lin H, Huang JF, Qiu JR, Zhang HL, Tang XJ, et al. Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis
of invasive ductal breast cancer. Exp Mol Pathol 2013;94:73-8.
120. Gui T, Dong X, Li R, Li Y, Wang Z. Identification of hepatocellular carcinoma-related genes with a machine learning and network
analysis. J Comput Biol 2015;22:63-71.
121. Ikeda Y, Imai Y, Kumagai H, Nosaka T, Morikawa Y, et al. Vasorin, a transforming growth factor beta-binding protein expressed in
vascular smooth muscle cells, modulates the arterial response to injury in vivo. Proc Natl Acad Sci USA 2004;101:10732-7.
122. Chen L, Yao JH, Zhang SH, Wang L, Song HD, et al. Slit-like 2, a novel zebrafish slit homologue that might involve in zebrafish
central neural and vascular morphogenesis. Biochem Biophys Res Commun 2005;336:364-71.
123. Li S, Li H, Yang X, Wang W, Huang A, et al. Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by
subtractive-EMSA-SELEX to clinic patient serum. Oncotarget 2015;6:10045-59.
124. Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, et al. Osteopontin as potential biomarker and therapeutic target in gastric and liver
cancers. World J Gastroenterol 2012;18:3923-30.
125. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J
Gastroenterol 2006;101:2051-9.
126. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, et al. Identification of osteopontin as a novel marker for early hepatocellular
carcinoma. Hepatology 2012;55:483-90.
127. Sun T, Tang Y, Sun D, Bu Q, Li P. Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-
analysis. Onco Targets Ther 2018;11:8925-35.
128. Fouad SA, Mohamed NA, Fawzy MW, Moustafa DA. Plasma osteopontin level in chronic liver disease and hepatocellular carcinoma.
Hepat Mon 2015;15:e30753.
129. Sun T, Li P, Sun D, Bu Q, Li G. Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and
meta-analysis. Medicine (Baltimore) 2018;97:e12954.
130. Liu K, Duan J, Liu H, Yang X, Yang J, et al. Precancer antiviral treatment reduces microvascular invasion of early-stage Hepatitis
B-related hepatocellular carcinoma. Sci Rep 2019;9:2220.
131. Sun BS1, Dong QZ, Ye QH, Sun HJ, Jia HL, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and
metastasis of human hepatocellular carcinoma. Hepatology 2008;48:1834-42.
132. Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, et al. Osteopontin induces growth of metastatic tumors in a preclinical model
of non-small lung cancer. J Exp Clin Cancer Res 2012;31:26.
133. Dai J, Li B, Shi J, Peng L, Zhang D, et al. A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo.
Cancer Immunol Immunother 2010;59:355-66.
134. Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell 2017;168:724-40.
135. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, et al. A phase I study on adoptive immunotherapy using gene-modified T
cells for ovarian cancer. Clin Cancer Res 2006;12:6106-15.
136. Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, et al. Treatment of metastatic renal cell carcinoma with
CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013;21:904-12.